Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

124.05USD
28 Apr 2017
Change (% chg)

$0.08 (+0.06%)
Prev Close
$123.97
Open
$124.21
Day's High
$124.30
Day's Low
$123.23
Volume
1,461,651
Avg. Vol
1,370,554
52-wk High
$127.61
52-wk Low
$94.42

Latest Key Developments (Source: Significant Developments)

Celgene on track to achieve or exceed 2020 forecast - CEO
Thursday, 27 Apr 2017 10:05am EDT 

April 27 (Reuters) - Celgene Corp :Celgene CEO says on track to achieve or exceed 2020 forecast.Celgene sees Otezla net sales rebounding, achieving full-year forecast.  Full Article

Acceleron says enrolment for late stage studies now expected to be completed in Q2
Thursday, 27 Apr 2017 07:35am EDT 

April 27 (Reuters) - Acceleron Pharma Inc :Acceleron provides clinical development updates on luspatercept program.Acceleron pharma inc says enrollment in MEDALIST and BELIEVE phase 3 studies now expected to be completed in q2 2017."we now look forward to reporting topline results from medalist and believe phase 3 studies in mid-2018".Acceleron pharma inc says acceleron and celgene also plan to initiate a third phase 3 trial of luspatercept.New phase 3 trial of luspatercept is expected to be initiated in early 2018.  Full Article

Diplomat Pharmacy on March 31,co, units, Celgene entered into pharmacy distribution, services agreement to be effective July 1, 2017
Thursday, 13 Apr 2017 08:15am EDT 

Celgene Corp : Diplomat Pharmacy Inc - on March 31,co, units, Celgene Corp entered into a pharmacy distribution and services agreement to be effective July 1, 2017 . Diplomat pharmacy - on effective date, agreement will replace co's current agreement with Celgene, as amended, which is set to expire on June 30, 2017 . Diplomat pharmacy - agreement sets forth terms and conditions on which company will purchase specialty drugs from Celgene and provide certain services .Diplomat Pharmacy - under terms services to be provided in connection with dispensing prescriptions for specialty drugs after expiration of current deal.  Full Article

Cipher Pharmaceuticals appoints Robert Tessarolo as CEO
Monday, 20 Mar 2017 04:00pm EDT 

Cipher Pharmaceuticals Inc : Cipher Pharmaceuticals appoints Robert Tessarolo as CEO . Says Tessarolo has been appointed president and chief executive officer of Cipher, effective April 17, 2017 .Cipher Pharmaceuticals Inc - Tessarolo most recently held position of vice president & general manager with Celgene Corporation.  Full Article

Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene
Monday, 13 Mar 2017 07:30am EDT 

Agios Pharmaceuticals Inc : Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene . Says Celgene will pay Agios an $8 million designation fee for MTAP pathway program . Agios Pharmaceuticals Inc - Celgene will have an opt-in right on program up through Phase 1 dose escalation for at least a $30 million fee . Agios Pharmaceuticals Inc - Agios will be eligible for up to $169 million in clinical and regulatory milestone payments .Agios Pharmaceuticals - co, Celgene to have global co-development and co-commercialization rights with worldwide 50/50 cost and profit share on MTAP pathway program.  Full Article

Juno Therapeutics reports qtrly net loss per share $0.51
Wednesday, 1 Mar 2017 04:05pm EST 

Juno Therapeutics Inc : Juno Therapeutics reports fourth quarter and 2016 financial results . Juno Therapeutics Inc - 2017 cash burn guidance of $270 million to $300 million . Juno Therapeutics Inc sees 2017 capital expenditures estimated to be between $22 million and $27 million . Juno Therapeutics Inc sees 2017 operating burn estimated to be between $245 million and $275 million . Juno Therapeutics Inc qtrly net loss per share $0.51 . Juno Therapeutics Inc qtrly revenue $21.2 million versus $ 4.2 million . Q4 earnings per share view $-0.61, revenue view $14.6 million -- Thomson Reuters I/B/E/S . Juno Therapeutics Inc qtrly net loss per share non-gaap $0.65 .Says "discontinuing development of jcar015 in r/r adult all to focus on defined cell product in this setting".  Full Article

FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT
Wednesday, 22 Feb 2017 04:02pm EST 

Celgene Corp : FDA expands indication for Revlimid® (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT) . Celgene Corp - FDA expanded existing indication for revlimid 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy .Celgene Corp- approval was based on two large studies comparing revlimid maintenance therapy versus no maintenance.  Full Article

Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis
Friday, 17 Feb 2017 07:30am EST 

Celgene Corp : Celgene announces positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis . Celgene Corp - safety and tolerability consistent with phase ii studies . Celgene Corp - study met its primary endpoint in reducing annualized relapse rate (arr) and measured secondary endpoints, compared to interferon (ifn) β-1a (avonex(reg)) . Says study met its primary endpoint .Celgene corp - confirmatory Phase III radiance trial data expected in q2 of 2017.  Full Article

Celgene receives second subpoena relating to past inquiry - SEC filing
Friday, 10 Feb 2017 06:04am EST 

Celgene Corp : Says received a second subpoena requesting materials primarily related to patient assistance to a past inquiry - sec filing . Celgene - subpoena recevied in nov 2016 requests materials related to patient assistance programs, including co's support of 501(c)(3) organizations .Celgene Corp says it is cooperating with the requests.  Full Article

Celgene CEO says tax reform could provide significant benefit to U.S. economy, healthcare industry - Conf Call
Thursday, 26 Jan 2017 09:59am EST 

Celgene Corp : Celgene says Q4 topline growth was predominantly volume driven with 14 percent of growth coming from product volume: Conf Call . Celgene says to continue its share repurchase program in 2017: Conf Call . Celgene says Abraxane growth in U.S. continues to be relatively stable in spite of significant competition in lung & breast cancer: Conf Call . Celgene says they have a strong chance of growing annually, each and every year throughout the decade beyond 2020: Conf Call . Celgene says keeping an open mind on capital allocation, including dividends : Conf Call . Celgene CEO is optimistic that Trump government is focusing on preserving, enhancing competitive marketplace as a way to balance value & economics of healthcare . Celgene CEO says they have to see how repeal & replacement of Obamacare plays out . Celgene CEO says in relation to Trump government: "We think it's going to be a pro-innovation, pro-industry policy environment" . Celgene CEO says overall Celgene is "guardedly optimistic" about expected corporate tax reform; cites growing optimism that it will be pro-innovation . Celgene CEO says tax reform could provide significant long-term benefits to U.S. economy, healthcare industry and "really level the playing field" Further company coverage: [CELG.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

More From Around the Web

Celgene 1st quarter sales miss; expects psoriasis drug rebound

Celgene Corp on Thursday reported lower-than-expected first-quarter revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.